title: Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?
authors.forename: Thierry
authors.initials: T
authors.lastname: Thevenot
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Cervoni
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Monnet
authors.forename: Frances
authors.initials: F
authors.lastname: Sheppard
authors.forename: Vincent Di
authors.initials: VD
authors.lastname: Martino
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001201:Ascites / Q000188:drug therapy* / Q000401:mortality; D000075202:Contraindications; D006801:Humans; D006975:Hypertension, Portal / Q000401:mortality / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000401:mortality; D011433:Propranolol / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol